The Food and Drug Administration recently authorized the temporary import of hydromorphone hydrochloride injection from Canada to address a critical shortage of the drug, an opioid pain medication. This product is marketed in Canada, and is manufactured in Canada by Sandoz Canada Inc. At this time, no other entity except Hospira is authorized by the FDA to import or distribute Sandoz Hydromorphone Hydrochloride Injection, USP 2 mg/mL ampules in the U.S. See the letter to health care providers for more details. 

Related News Articles

Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…